- Home
- MNPR vs BWMX Comparison
MNPR vs BWMX Comparison
Compare MNPR & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | BWMX |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | Mexico |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.6M | 495.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNPR | BWMX |
|---|---|---|
| Price | $75.05 | $14.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $97.83 | $22.50 |
| AVG Volume (30 Days) | ★ 163.8K | 28.9K |
| Earning Date | 11-13-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 10.54% |
| EPS Growth | N/A | ★ 15.49 |
| EPS | N/A | ★ 1.49 |
| Revenue | N/A | ★ $775,128,445.00 |
| Revenue This Year | N/A | $3.50 |
| Revenue Next Year | N/A | $5.30 |
| P/E Ratio | ★ N/A | $9.45 |
| Revenue Growth | N/A | ★ 3.60 |
| 52 Week Low | $21.00 | $7.00 |
| 52 Week High | $105.00 | $15.00 |
Technical Indicators
Market Signals| Indicator | MNPR | BWMX |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 49.02 |
| Support Level | $74.51 | $13.47 |
| Resistance Level | $79.31 | $14.50 |
| Average True Range (ATR) | 6.38 | 0.43 |
| MACD | -0.93 | -0.06 |
| Stochastic Oscillator | 6.10 | 42.86 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About BWMX Betterware de Mexico S.A.P.I. de C.V.
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.